Research Leaders / KOL Map

Radioligand Therapy: Research Leaders and Landscape

The most active researchers, institutions, and subtopics in Radioligand Therapy, from recent PubMed records. Public authorship only, every figure verifiable by PMID.

Analyzed 422 recent PubMed papers (2021-2026) matching "radioligand therapy prostate cancer lutetium". Source: NLM PubMed. Generated July 2026.

Top research leaders (by recent publication volume)

#ResearcherAffiliationPapers
1Eiber MatthiasTechnical University of Munich29
2Ezziddin SamerSaarland University - Medical Center19
3Rosar FlorianSaarland University - Medical Center17
4Bartholomä MarkSaarland University - Medical Center16
5Maus StephanSaarland University - Medical Center15
6Tauber RobertTechnical University of Munich15
7Herrmann KenUniversity of Duisburg-Essen and German Cancer Consortium 14
8Rahbar KambizUniversity Hospital Münster14
9Burgard CarolineSaarland University - Medical Center13
10Schaefer-Schuler AndreaSaarland University - Medical Center12
11Khreish FadiSaarland University - Medical Center11
12Calais JeremieUniversity of California Los Angeles11
13Blickle ArneSaarland University - Medical Center10
14Seifert RobertBern University Hospital10
15Afshar-Oromieh AliBern University Hospital10
16Nagarajah JamesRadboud University Medical Center10
17Lapa ConstantinUniversity of Augsburg9
18D'Alessandria CalogeroTechnical University of Munich9

Ranked by recent publication volume; names not yet disambiguated and not citation-weighted. The full brief adds ORCID disambiguation, citation weighting, and clinical-trial investigator data.

Leading institutions

Technical University of Munich (20), University of Melbourne (12), University Hospital Würzburg (11), University Hospital (11), University Hospital Münster (9), Peking Union Medical College Hospital (8), Peter MacCallum Cancer Centre (8), University of Augsburg (8), Medical University of Vienna (8), Tehran University of Medical Sciences (7)

Active subtopics

Lutetium (304), Prostatic Neoplasms, Castration-Resistant (253), Prostate-Specific Antigen (239), Radioisotopes (210), Dipeptides (197), Heterocyclic Compounds, 1-Ring (186), Radiopharmaceuticals (179), Treatment Outcome (153), Retrospective Studies (102), Glutamate Carboxypeptidase II (96)

Top journals

European journal of nuclear medicine and molecular imaging (68), Journal of nuclear medicine : official publication, Society of Nuclear Medicine (31), Clinical nuclear medicine (26), Cancers (21), Theranostics (13), Nuclear medicine communications (9)

Representative recent papers

A Spatiotemporal Image-Guided Model of Radiopharmaceutical Transport in Heterogeneous Vasculature Prostate Tumor: A Computational (2026) · PMID 42472416

The experience of Nuclear Medicine Department of G.N.A. Evangelismos on the therapy with (2026) · PMID 42472316

Lutetium-177-PSMA radioligand therapy in metastatic hormone-sensitive prostate cancer: A systematic review of efficacy, safety, an (2026) · PMID 42471290

PSMA-Targeted Radioligand Therapy Beyond the Post-Taxane Setting: A Review of Evidence Across the Prostate Cancer Spectrum. (2026) · PMID 42449702

Novel Risk Scoring System for Patients with Metastatic Castration Resistant Prostate Cancer Treated with Lutetium-177-PSMA-617. (2026) · PMID 42434975

Want the full cited brief?

A full Radioligand Therapy brief adds citation weighting, name disambiguation, clinical-trial investigators, and a cited PDF, scoped to your exact molecule, competitor set, or region.

Try the live tool Contact us